Mild Dementia
Data support early, continued lecanemab dosing for Alzheimer’s
In an open-label extension of the CLARITY-AD study, treatment with IV lecanemab was associated with significant improvement in Alzheimer’s disease-related pathology, continuing a positive treatment effect from the randomization phase.
Plasma assays ‘accurately rule out’ AD-related pathology
Plasma pTau181 in combination with ApoE4 assays registered a high degree of accuracy in ruling out patients with a low probability of amyloid pathology in the early stages of Alzheimer’s disease, according to a poster presentation at CTAD.
FDA approves injectable Kisunla for early symptomatic Alzheimer’s disease
The FDA approved Kisunla for adults with early symptomatic Alzheimer’s disease, including those with mild cognitive impairment and mild dementia with confirmed amyloid pathology.
FDA advisory committee backs donanemab for early-stage Alzheimer’s
An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.
Surgery for hip fracture may decrease mortality in community-dwelling adults with dementia
Among community-dwelling adults with dementia, surgical intervention of femoral head and neck fractures was associated with decreased mortality compared with nonsurgical treatment, according to published results.
Neurologists mired in ‘wait and see’ approach to Leqembi prescription, administration
The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.
Combination adrenergic activator improves several cognitive domains in patients with AD, PD
CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.
FDA to further review study of donanemab for early Alzheimer’s
The FDA will convene an advisory committee meeting to discuss the safety and efficacy of donanemab in early symptomatic Alzheimer's disease, according to the manufacturer.
Association strong between MCI, related comorbidities, but decreases with age
For early detection of Alzheimer’s disease in older adults, comorbidities remained strongly associated with mild cognitive impairment, but prediction decreased with age, according to a poster presentation at CTAD.
Neurocognitive composite accurately detected symptom worsening in Alzheimer’s
Time-dependent worsening of cognition and function among a cohort of individuals with biomarker-proven Alzheimer’s disease or dementia was accurately detected by a composite neurocognitive measure.